Welcome to our dedicated page for Ernexa SEC filings (Ticker: ERNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ernexa Therapeutics Inc. (NASDAQ: ERNA) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into Ernexa’s development-stage biotechnology business, which focuses on iPSC-derived iMSC cell therapies for advanced cancer and autoimmune disease.
Through this page, readers can review annual reports on Form 10-K and quarterly reports on Form 10-Q to understand Ernexa’s financial position, operating expenses, research and development priorities, and risk disclosures typical of early-stage biotechnology companies. Current reports on Form 8-K capture material events, such as the disclosed change in Ernexa’s independent registered public accounting firm and references to going concern considerations and internal control matters.
For those following governance and ownership, proxy statements and related filings can provide information on board structure and executive compensation, while beneficial ownership reports and Form 4 filings allow tracking of insider transactions by directors, officers, and significant shareholders, when available. Together, these documents help investors and analysts evaluate how Ernexa manages its cell therapy programs, capital resources, and corporate oversight.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, explain complex sections in plain language, and draw attention to items such as going concern notes, material weaknesses in internal control, or important changes in auditors. Real-time updates from EDGAR ensure that new Ernexa filings appear promptly, while AI-generated overviews of 10-Ks, 10-Qs, 8-Ks, and Form 4 submissions can save time for users seeking to understand the regulatory record behind the ERNA ticker.
Ernexa Therapeutics Inc. disclosed that Nasdaq has notified the company its common stock no longer meets the minimum bid price requirement of $1.00 per share for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2). Because Ernexa completed a reverse stock split within the past year, it is not eligible for the standard 180‑day automatic grace period and instead plans to request a hearing before a Nasdaq Hearing Panel. The hearing request will stay any suspension or delisting action while the Panel reviews the case and may grant an extension of up to 180 days from the notice date, but there is no assurance the company will regain compliance or maintain its Nasdaq Capital Market listing.
Ernexa Therapeutics Inc. filed a shelf registration to offer up to $50,000,000 of securities and a sales agreement prospectus supplement establishing an ATM program to sell up to $9,248,276 of common stock through Brookline Capital Markets. The prospectus notes 29,154,431 shares outstanding as of March 12, 2026 and a public float of $27,744,830.12.
The company describes its lead preclinical iMSC candidate ERNA-101, recent pre-IND FDA alignment, a completed February 10, 2026 public offering that generated net proceeds of approximately $9.5 million, and Nasdaq compliance matters tied to the $1.00 minimum bid rule and a recent reverse stock split.
Ernexa Therapeutics Inc. files its 2025 Annual Report describing a preclinical-stage synthetic allogeneic iMSC platform focused on cancer and autoimmune diseases. Lead candidate ERNA-101 for platinum‑resistant ovarian cancer showed preclinical tumor growth reduction and survival benefit and followed a successful FDA pre‑IND meeting.
The company plans IND‑enabling work and an IND filing in 2026, targeting a Phase I investigator‑sponsored trial in the second half of 2026, and is advancing ERNA‑201 for autoimmune disorders. Ernexa relies heavily on an exclusive license with Factor Bioscience covering 13 patent families and 33 granted patents as of March 12, 2026.
The filing highlights substantial capital needs and states current cash is insufficient to fund operations for 12 months after the financial statement issuance date, raising going concern risk. Stockholders’ equity was about $2.4 million at December 31, 2025, and a February 10, 2026 public offering generated roughly $9.5 million in net proceeds, lifting equity above Nasdaq’s $2.5 million threshold. As of March 12, 2026, Ernexa had 29,154,431 common shares outstanding and reported non‑affiliate market value of about $17.5 million as of June 30, 2025.
The report warns of possible Nasdaq delisting if the bid price remains below $1.00 following a recent reverse split, intense competition in cell therapy and ovarian cancer, complex manufacturing and regulatory pathways for iPSC‑derived products, and heavy dependence on the Factor license and outsourced manufacturing relationships.
Ernexa Therapeutics Inc. furnished an updated investor presentation on February 26, 2026, as Exhibit 99.1 to a Form 8-K. The deck refreshes a prior presentation from December 11, 2025 and is also available through the Investor Relations section of the company’s website.
The company explains that it routinely uses its website to share press releases, investor presentations and financial information, and encourages investors to monitor the News and Investor Relations pages. The material in Item 7.01 and Exhibit 99.1 is furnished, not filed, and is not subject to Exchange Act Section 18 liabilities or automatically incorporated into other SEC filings.
Charles Cherington filed Amendment No. 8 to report beneficial ownership of 10,791,335 Ernexa Therapeutics common shares and equivalents, representing 34.7% of the class. This total includes 6,779,440 common shares, 4,000,000 shares issuable upon warrant exercise, and 11,895 shares issuable from Series A preferred stock.
The filing explains that Ernexa completed a best efforts public offering on February 10, 2026, issuing 21,000,000 common shares and equivalents at a combined price of $0.50 per share (or $0.49 per pre-funded warrant) and warrants to purchase 21,000,000 shares at $0.68 per share. Cherington acquired 4,000,000 common shares and 4,000,000 warrants in this transaction and states he has no present plans for corporate control changes.
Ernexa Therapeutics Inc. insider and 10% owner Cherington Charles bought 4,000,000 shares of common stock on February 10, 2026, in a follow-on offering pursuant to a prospectus supplement dated February 6, 2026. The combined purchase price per share of common stock and accompanying warrant was $0.50.
At the same time, Cherington Charles acquired 4,000,000 warrants to purchase common stock. These warrants will expire on the earlier of February 10, 2031 or the 180th calendar day following the public release of clinical trial data from the first cohort of the Phase 1 study of ERNA-101.
Ernexa Therapeutics Inc. entered into agreements for a best-efforts public offering of common stock and warrants, raising approximately $10.5 million in gross proceeds. The deal covers 21,000,000 shares of common stock (or equivalents) and warrants to purchase up to 21,000,000 shares, at a combined price of $0.50 per share (or equivalent) and warrant.
The warrants are immediately exercisable at $0.68 per share and will expire on the earlier of five years from issuance or 180 days after the first-cohort Phase 1 ERNA-101 data release. Pre-funded warrants for 2,000,000 shares carry a $0.01 exercise price. The Nasdaq-listed warrants trade under the symbol ERNAW.
Brookline Capital Markets, a division of Arcadia Securities, acted as placement agent, earning cash fees and 231,576 shares as compensation. Ernexa plans to use net proceeds to advance its cell therapy programs, working capital, and general corporate purposes, and has agreed to 90-day issuance restrictions and officer/director lock-ups.
Ernexa Therapeutics Inc. is conducting a reasonable best-efforts public offering of 21,000,000 shares of common stock (or pre-funded warrants in lieu thereof), each paired with a Common Warrant to purchase one share, plus 231,576 Agent’s Shares as compensation to the placement agent. The combined public offering price is $0.50 per share of Common Stock and accompanying Common Warrant, and $0.49 per pre-funded warrant and accompanying Common Warrant, for total gross proceeds of $10,480,000.00 and estimated proceeds before expenses of $10,007,360.00. The Common Warrants have a $0.68 exercise price, are immediately exercisable, and may expire as early as 180 days after public release of first-cohort Phase 1 ERNA-101 data. This is a no-minimum, best-efforts deal, so the company may raise less than the full amount, and investors will not receive refunds. Ernexa is a preclinical synthetic iMSC therapy company that discloses it will not have sufficient capital to fund operations for 12 months without additional financing and highlights substantial ongoing losses and significant business and regulatory risks.
Ernexa Therapeutics Inc. is registering up to 13,586,956 shares of common stock, associated pre-funded warrants and common warrants, plus up to 203,804 Agent’s Shares, in a primary, best-efforts offering with no minimum amount required to close.
Each common share is sold together with a common warrant to buy one additional share, at a combined price assumed at $0.92, the February 3, 2026 Nasdaq closing price. Certain large investors may instead buy pre-funded warrants priced $0.005 below the share price, with a $0.005 exercise price and no expiration until fully exercised.
The common warrants will be immediately exercisable, with an exercise price set at the Nasdaq closing price at pricing, and will expire on the earlier of five years from issuance or 180 days after public release of first-cohort Phase 1 data for ERNA-101. Common stock trades on Nasdaq as “ERNA,” and Ernexa has applied to list the common warrants as “ERNAW.”
The company highlights significant ongoing losses, a large accumulated deficit and a need for substantial additional capital, warning it may not be able to continue as a going concern without new funding. It also discloses heavy reliance on licensed intellectual property from Factor Bioscience and outlines extensive business, technology, regulatory, and offering-related risks, including potentially significant dilution and the absence of any dividend plan.